GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » Equity-to-Asset

CymaBay Therapeutics (CymaBay Therapeutics) Equity-to-Asset : 0.67 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. CymaBay Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $292.26 Mil. CymaBay Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $434.69 Mil. Therefore, CymaBay Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.67.

The historical rank and industry rank for CymaBay Therapeutics's Equity-to-Asset or its related term are showing as below:

CBAY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.2   Med: 0.66   Max: 0.93
Current: 0.67

During the past 12 years, the highest Equity to Asset Ratio of CymaBay Therapeutics was 0.93. The lowest was 0.20. And the median was 0.66.

CBAY's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs CBAY: 0.67

CymaBay Therapeutics Equity-to-Asset Historical Data

The historical data trend for CymaBay Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CymaBay Therapeutics Equity-to-Asset Chart

CymaBay Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.91 0.93 0.66 0.26 0.67

CymaBay Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.43 0.48 0.72 0.67

Competitive Comparison of CymaBay Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, CymaBay Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CymaBay Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where CymaBay Therapeutics's Equity-to-Asset falls into.



CymaBay Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

CymaBay Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=292.256/434.686
=0.67

CymaBay Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=292.256/434.686
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CymaBay Therapeutics  (NAS:CBAY) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


CymaBay Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Traded in Other Exchanges
Address
7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Executives
Charles Mcwherter officer: Chief Scientific Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold officer: Vice President, Finance C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan officer: General Counsel C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling director C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah director, officer: Chief Executive Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster director 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam officer: Chief Financial Officer 7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim officer: Chief Medical Officer C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans director
Lewis J Stuart officer: Chief Commercial Officer 3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc 10 percent owner 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh 10 percent owner C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills director 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103

CymaBay Therapeutics (CymaBay Therapeutics) Headlines

From GuruFocus